Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by T. Faustmann
Efficacy and Safety of the Selective Progesterone Receptor Modulator (PRM) Vilaprisan - 24-Week Outcomes From Asteroid 2
Fertility and Sterility
Gynecology
Reproductive Medicine
Obstetrics
Baseline Characteristics From >27,000 Women With Endometriosis Enrolled in the VIPOS Study
Fertility and Sterility
Gynecology
Reproductive Medicine
Obstetrics
Related publications
Non-Surgical Treatment of Uterine Fibroids. Efficacy of the Selective Progesterone Receptor Modulator
Medical Council
Front Cover: Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies (ChemMedChem 21/2018)
ChemMedChem
Organic Chemistry
Molecular Medicine
Pharmacology
Biochemistry
Toxicology
Drug Discovery
Pharmaceutics
Efficacy and Safety of Repaglinide Added to Sitagliptin in Japanese Patients With Type 2 Diabetes: A Randomized 24-Week Open-Label Clinical Trial
Endocrine Journal
Endocrinology
Metabolism
Diabetes
Efficacy and Safety of Fixed-Dose Combinations of Aclidinium Bromide/Formoterol Fumarate: The 24-Week, Randomized, Placebo-Controlled AUGMENT COPD Study
Respiratory Research
Pulmonary
Respiratory Medicine
Treatment of Resistant Depression in Adolescents (TORDIA): Week 24 Outcomes
American Journal of Psychiatry
Psychiatry
Mental Health
Efficacy and Safety of the Novel Selective Nicotinic Acetylcholine Receptor Partial Agonist, Varenicline, for Smoking Cessation
Archives of Internal Medicine
Noise Trauma and Systemic Application of the Selective Glucocorticoid Receptor Modulator Compound A
Journal of Negative Results in BioMedicine
Genetics
Pharmacology
Molecular Biology
Biochemistry
Medicine
Toxicology
Pharmaceutics
The Selective Estrogen Receptor Modulator Raloxifene Inhibits Neutrophil Extracellular Trap Formation
Frontiers in Immunology
Allergy
Immunology
Safety and Efficacy From an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents With Schizophrenia
Journal of Child and Adolescent Psychopharmacology
Mental Health
Child Health
Pharmacology
Perinatology
Psychiatry
Pediatrics
